GEN1160 was being tested in a phase I/II study in patients with renal cell carcinoma, nasopharyngeal cancer and non‑Hodgkin lymphoma. The trial has now been terminated due to insufficient recruitment combined with a strategic reprioritization of the company’s pipeline, according to a company statement.
Genmab drops another ADC candidate from billion‑dollar ProfoundBio deal
Danish biotech Genmab has discontinued development of its antibody‑drug conjugate (ADC) candidate GEN1160, citing low patient enrollment in an early‑stage cancer trial.
Advertisement
BREAKING